Published on Hong Kong Sanatorium & Hospital Mobile Site (https://mobile.hksh.com)

首页 > [2025-10-23] HKSH Medical Group Announces World’s First Study on Multi-Target, Real-Time Stereotactic Total Ablative Radiotherapy with MR-LINAC for Oligometastatic Prostate Cancer Achieving 100% 3-Year Survival Rate without Severe Side Effects

[2025-10-23] HKSH Medical Group Announces World’s First Study on Multi-Target, Real-Time Stereotactic Total Ablative Radiotherapy with MR-LINAC for Oligometastatic Prostate Cancer Achieving 100% 3-Year Survival Rate without Severe Side Effects

CADLanceCheung 在 2025-10-23 提交
Undefined
pdf: 
PDF icon ba6ae5b1ebd629792465a80340bc0e31.pdf [1]
category_en: 
2025 [2]
Source URL: https://mobile.hksh.com/zh-cn/pdf-en/2025-10-23-hksh-medical-group-announces-world%E2%80%99s-first-study-multi-target-real-time

Links
[1] https://mobile.hksh.com/sites/default/files/publications/en/ba6ae5b1ebd629792465a80340bc0e31.pdf
[2] https://mobile.hksh.com/zh-cn/hierarchicaluploaden/2025